✦ LIBER ✦

No influence of the polymorphismsCYP2C19andCYP2D6on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

✍ Scribed by Annette J Vangsted; Karen Søeby; Tobias W Klausen; Niels Abildgaard; Niels F Andersen; Peter Gimsing; Henrik Gregersen; Ulla Vogel; Thomas Werge; Henrik B Rasmussen

Book ID: 115010135
Publisher: BioMed Central
Year: 2010
Tongue: English
Weight: 283 KB
Volume: 10
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-10-404

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

Thalidomide, lenalidomide and bortezomib

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma

✍ Laubach, Jacob P; Schlossman, Robert L; Mitsiades, Constantine S; Anderson, Kenn 📂 Article 📅 2011 🏛 Expert Reviews 🌐 English ⚖ 357 KB

Maintenance therapy with bortezomib plus

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

✍ Mateos, M.-V.; Oriol, A.; Martinez-Lopez, J.; Gutierrez, N.; Teruel, A.-I.; Lope 📂 Article 📅 2012 🏛 American Society of Hematology 🌐 English ⚖ 269 KB

Efficacy of single-agent bortezomib vs.

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison

✍ H. Miles Prince; Michael Adena; Dell Kingsford Smith; Judy Hertel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB

Efficacy of stem cell mobilization in pa

Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen

✍ Sung-Hoon Jung, Hyungchul Park, Jae-Sook Ahn… 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 239 KB

Bortezomib, melphalan, and prednisone ve

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

✍ María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; An 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 255 KB